Get the Stockscreener App
21.02
1.36%
-0.29
After Hours:
21.98
0.96
+4.57%
Cidara Therapeutics Inc stock is traded at $21.02, with a volume of 391.88K.
It is down -1.36% in the last 24 hours and down -21.86% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$21.31
Open:
$21.41
24h Volume:
391.88K
Relative Volume:
2.26
Market Cap:
$339.42M
Revenue:
$56.54M
Net Income/Loss:
$-30.70M
P/E Ratio:
-53.90
EPS:
-0.39
Net Cash Flow:
$-31.05M
1W Performance:
-7.97%
1M Performance:
-21.86%
6M Performance:
-9.47%
1Y Performance:
+79.66%
1-Day Range:
$20.16
$21.53
1-Week Range:
$20.16
$23.86
52-Week Range:
$10.14
$28.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
21.02 | 339.42M | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
(CDTX) Proactive Strategies - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Receives Buy Rating from HC Wainwrigh - GuruFocus
H.C. Wainwright assumes coverage on Cidara stock with buy rating By Investing.com - Investing.com UK
H.C. Wainwright Initiates Coverage on Cidara Therapeutics (CDTX) with Strong Outlook | CDTX Stock News - GuruFocus
Cidara Therapeutics (NASDAQ:CDTX) Given Overweight Rating at Cantor Fitzgerald - Defense World
Cidara Therapeutics (CDTX) Reiterates Overweight Rating by Canto - GuruFocus
(CDTX) Investment Analysis - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Holdings in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Cidara Therapeutics stock maintains strong rating at Citizens JMP By Investing.com - Investing.com Canada
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $36.00 at Needham & Company LLC - Defense World
Insider Buying: Chrysa Mineo Acquires Shares of Cidara Therapeutics Inc (CDTX) - GuruFocus
Needham raises Cidara Therapeutics stock price target to $36 - Investing.com
Cidara Therapeutics (CDTX) Price Target Raised by Needham | CDTX Stock News - GuruFocus
Cidara Therapeutics (NASDAQ:CDTX) Given Market Outperform Rating at JMP Securities - Defense World
Cidara Therapeutics (CDTX) Maintains Market Outperform Rating | CDTX Stock News - GuruFocus
12,714 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Purchased by Jane Street Group LLC - Defense World
Northern Trust Corp Has $913,000 Stock Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals - Value The Markets
Cidara Therapeutics (NASDAQ:CDTX) Given “Market Outperform” Rating at JMP Securities - Defense World
JMP Securities Reiterates Market Outperform Rating for Cidara Therapeutics (CDTX) | CDTX Stock News - GuruFocus
Cidara stock target holds at $47 by JMP on trial confidence - Investing.com Canada
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World
(CDTX) On The My Stocks Page - news.stocktradersdaily.com
Cidara Therapeutics: All Stars Aligning In Favor Of CD388 (NASDAQ:CDTX) - Seeking Alpha
Royal Bank of Canada Increases Cidara Therapeutics (NASDAQ:CDTX) Price Target to $35.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Earns Buy Rating from Needham & Company LLC - Defense World
Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RB - GuruFocus
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RBC Capital | CDTX Stock News - GuruFocus
RBC Capital Ups Price Target for Cidara Therapeutics (CDTX) Amid Optimism | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX): Analyst Reiterates Buy Rating | CDTX Stock News - GuruFocus
RBC Raises Price Target on Cidara Therapeutics to $35 From $31, Keeps Outperform, Speculative Risk - marketscreener.com
Transcript : Cidara Therapeutics, Inc.Special Call - marketscreener.com
Seasonal Influenza Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis - Barchart.com
Seasonal Influenza Market to Reach New Heights in Growth by 2034, - openPR.com
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
CDTX Stock Price and Chart — NASDAQ:CDTX - TradingView
When (CDTX) Moves Investors should Listen - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Target Price Raised by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenh - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics price target raised to $50 from $35 at Guggenheim - TipRanks
Cidara Therapeutics to Host Virtual R&D Day to Discuss - GlobeNewswire
Revolutionary Once-Per-Year Universal Flu Prevention: Cidara Unveils Phase 2b Trial Updates at R&D Day - Stock Titan
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 - The Manila Times
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call - MSN
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $35.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, JMP Securities Analyst Says - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Guggenheim Raises Price Target for Cidara Therapeutics (CDTX) to $35.00 | CDTX Stock News - GuruFocus
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cidara Therapeutics Inc Stock (CDTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
| Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):